1. Home
  2. WVE vs GBX Comparison

WVE vs GBX Comparison

Compare WVE & GBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WVE
  • GBX
  • Stock Information
  • Founded
  • WVE 2012
  • GBX 1974
  • Country
  • WVE Singapore
  • GBX United States
  • Employees
  • WVE N/A
  • GBX N/A
  • Industry
  • WVE Biotechnology: Pharmaceutical Preparations
  • GBX Railroads
  • Sector
  • WVE Health Care
  • GBX Industrials
  • Exchange
  • WVE Nasdaq
  • GBX Nasdaq
  • Market Cap
  • WVE 1.7B
  • GBX 1.8B
  • IPO Year
  • WVE 2015
  • GBX N/A
  • Fundamental
  • Price
  • WVE $7.74
  • GBX $51.04
  • Analyst Decision
  • WVE Strong Buy
  • GBX Hold
  • Analyst Count
  • WVE 11
  • GBX 3
  • Target Price
  • WVE $22.00
  • GBX $64.00
  • AVG Volume (30 Days)
  • WVE 1.3M
  • GBX 412.0K
  • Earning Date
  • WVE 03-04-2025
  • GBX 04-08-2025
  • Dividend Yield
  • WVE N/A
  • GBX 2.36%
  • EPS Growth
  • WVE N/A
  • GBX 73.06
  • EPS
  • WVE N/A
  • GBX 5.73
  • Revenue
  • WVE $108,302,000.00
  • GBX $3,611,800,000.00
  • Revenue This Year
  • WVE N/A
  • GBX $2.49
  • Revenue Next Year
  • WVE $33.28
  • GBX $2.20
  • P/E Ratio
  • WVE N/A
  • GBX $8.90
  • Revenue Growth
  • WVE N/A
  • GBX N/A
  • 52 Week Low
  • WVE $4.25
  • GBX $41.40
  • 52 Week High
  • WVE $16.74
  • GBX $71.06
  • Technical
  • Relative Strength Index (RSI)
  • WVE 31.52
  • GBX 30.06
  • Support Level
  • WVE $9.43
  • GBX $50.20
  • Resistance Level
  • WVE $10.91
  • GBX $55.12
  • Average True Range (ATR)
  • WVE 0.63
  • GBX 1.33
  • MACD
  • WVE -0.18
  • GBX -0.08
  • Stochastic Oscillator
  • WVE 3.21
  • GBX 15.33

About WVE Wave Life Sciences Ltd.

WAVE Life Sciences Ltd is unlocking the broad potential of RNA medicines also known as oligonucleotides, it targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

About GBX Greenbrier Companies Inc. (The)

Greenbrier Companies Inc designs, manufactures, and markets railroad freight car equipment in North America and Europe, marine barges in North America and provides wheel services, railcar refurbishment, and parts, leasing and other services to the railroad. Its segments include Manufacturing, Maintenance Services and Leasing & Management Services. The company generates a majority of its revenue from the manufacturing segment. Geographically, it derives a majority of revenue from the United States.

Share on Social Networks: